Patients receiving targeted anticancer treatments are at a significant risk of developing xerosis, or abnormal dryness, according to Dr. Johannah Valentine and her associates.

In a systematic review and meta-analysis of clinical trials involving 58 targeted agents, nearly 18% of all patients developed xerosis, with 1% of patients developing high-grade xerosis. The incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions, and reporting may vary among physicians and institutions, the researchers said.

Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality-of-life impairment, the investigators recommended.

Read the full article at the Journal of the American Academy of Dermatology (doi:10.1016/j.jaad.2014.12.010).


You May Also Like

WCD: Cut simple carbs to clear acne

AT WCD 2015 VANCOUVER, B.C. (FRONTLINE MEDICAL NEWS) – Mounting evidence suggests that consuming ...

New acellular pertussis vaccine may solve waning immunogenicity problem

AT ESPID 2017 MADRID (FRONTLINE MEDICAL NEWS) – A novel, monovalent, acellular pertussis vaccine ...